Related Experiment Video
Updated: Sep 5, 2025
Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
Published on: January 22, 2019
A small-molecule Skp1 inhibitor elicits cell death by p53-dependent mechanism
Muzammal Hussain1,2,3, Yongzhi Lu1,4, Muqddas Tariq1,4
1State Key Laboratory of Respiratory Disease, Center for Chemical Biology and Drug Discovery, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, 190 Kaiyuan Avenue, Science Park, Guangzhou 510530, China.
Abstract:
Skp1 overexpression promotes tumor growth, whereas reduced Skp1 activity is also linked with genomic instability and neoplastic transformation. This highlights the need to gain better understanding of Skp1 biology in cancer settings. To this context, potent and cellularly active small-molecule Skp1 inhibitors may be of great value. Using a hypothesis-driven, structure-guided approach, we herein identify Z0933M as a potent Skp1 inhibitor with KD ∼0.054 μM. Z0933M occupies a hydrophobic hotspot (P1) - encompassing an aromatic cage of two phenylalanines (F101 and F139) - alongside C-terminal extension of Skp1 and, thus, hampers its ability to interact with F-box proteins, a prerequisite step to constitute intact and active SCF E3 ligase(s) complexes. In cellulo, Z0933M disrupted SCF E3 ligase(s) functioning, recapitulated previously reported effects of Skp1-reduced activity, and elicited cell death by a p53-dependent mechanism. We propose Z0933M as valuable tool for future efforts toward probing Skp1 cancer biology, with implications for cancer therapy.
Insights
Researchers identified Z0933M, a potent small-molecule inhibitor of Skp1 (Suppressor of kinase protein 1). This compound disrupts SCF E3 ligase complexes, offering a new tool for cancer research and potential therapeutic strategies.
Area of Science:
- Molecular Biology
- Cancer Biology
- Drug Discovery
Background:
- Skp1 (Suppressor of kinase protein 1) plays a dual role in cancer, with overexpression promoting tumor growth and reduced activity linked to genomic instability.
- Understanding Skp1's function in cancer is crucial for developing targeted therapies.
- Small-molecule inhibitors of Skp1 are needed to investigate its role in cancer settings.
Purpose of the Study:
- To identify and characterize a potent, cellularly active small-molecule inhibitor of Skp1.
- To elucidate the mechanism of action of the identified inhibitor.
- To evaluate the potential of this inhibitor as a tool for cancer research and therapy.
Main Methods:
- Structure-guided drug design approach.
- Biochemical assays to determine inhibitor potency (KD).
- Cellular assays to assess inhibitor effects on SCF E3 ligase function and cell viability.
Main Results:
- Identification of Z0933M as a potent Skp1 inhibitor with a KD of approximately 0.054 μM.
- Z0933M binds to a hydrophobic hotspot in Skp1, hindering its interaction with F-box proteins and disrupting SCF E3 ligase complex formation.
- Z0933M effectively inhibits SCF E3 ligase function in cells, leading to p53-dependent cell death.
Conclusions:
- Z0933M is a valuable chemical probe for studying Skp1 biology in cancer.
- The findings suggest potential therapeutic implications for targeting Skp1 in cancer treatment.
- Further research using Z0933M can advance our understanding of Skp1's role in tumorigenesis.
More Related Videos
Related Concept Videos
01:31The Intrinsic Apoptotic Pathway
02:34Inhibition of Cdk Activity
01:23Negative Regulator Molecules
02:23Abnormal Proliferation
02:37DNA Damage can Stall the Cell Cycle
01:19Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...